Inhibrx Biosciences (INBX) Expected to Announce Earnings on Tuesday

Inhibrx Biosciences (NASDAQ:INBX) is expected to release its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Inhibrx Biosciences to post earnings of ($2.08) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, April 3, 2026 at 5:00 PM ET.

Inhibrx Biosciences (NASDAQ:INBX) last released its quarterly earnings results on Thursday, March 19th. The company reported ($2.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.08) by ($0.03). On average, analysts expect Inhibrx Biosciences to post $105 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Inhibrx Biosciences Trading Up 6.1%

NASDAQ:INBX opened at $64.63 on Tuesday. The firm’s fifty day moving average is $75.28 and its 200-day moving average is $66.30. The company has a debt-to-equity ratio of 12.58, a quick ratio of 3.93 and a current ratio of 3.93. Inhibrx Biosciences has a 52 week low of $10.81 and a 52 week high of $94.57. The firm has a market cap of $944.24 million, a P/E ratio of -7.15 and a beta of 1.50.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Inhibrx Biosciences in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Inhibrx Biosciences has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Inhibrx Biosciences

Several institutional investors have recently added to or reduced their stakes in INBX. Persistent Asset Partners Ltd acquired a new stake in shares of Inhibrx Biosciences during the 4th quarter worth approximately $27,000. Daiwa Securities Group Inc. acquired a new position in shares of Inhibrx Biosciences during the 4th quarter valued at $66,000. Public Employees Retirement System of Ohio acquired a new position in shares of Inhibrx Biosciences during the 3rd quarter valued at $40,000. Diadema Partners LP bought a new position in Inhibrx Biosciences during the fourth quarter worth $103,000. Finally, BNP Paribas Financial Markets boosted its stake in Inhibrx Biosciences by 71.9% during the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock worth $64,000 after acquiring an additional 789 shares in the last quarter. 82.46% of the stock is owned by institutional investors and hedge funds.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.